Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
(NASDAQ: ACRS) Delayed: 4.84 +0.34 (7.56%)
Previous Close $4.50    52 Week High $33.88 
Open $4.55    52 Week Low $14.12 
Day High $4.93    P/E N/A 
Day Low $4.50    EPS $0.00 
Volume 1,819,281